Author:
Hafeez Abdul,Afzal Usmani Shazia
Abstract
Diseases related to the brain are causing a huge problem worldwide. Different drug formulations are available for the management of brain-related disorders, but due to less drug availability for the brain and non-specificity, it becomes difficult to completely cure life-threatening brain disorders. The blood-brain barrier (BBB) restricts the entry of drug molecules/drug-loaded carriers because of the presence of various efflux transporters and drug inactivating enzymes. Researchers have identified an intranasal route for direct delivery to the brain, bypassing BBB. Nanotechnology-enabled lipid-based drug carrier systems have shown potential for the management of brain diseases through nose-to-brain delivery. Liposomes are the most extensively investigated carrier systems because of biocompatibility, controlled release characteristics, easy surface modification, and biodegradability. This chapter highlights the important aspects of nose-to-brain delivery and strategies for enhancing the availability of drugs through liposomes in the management of different brain-related diseases.
Reference64 articles.
1. Catalá-López F, Hutton B, Driver JA, Page MJ, Ridao M, Valderas JM, et al. Cancer and central nervous system disorders: protocol for an umbrella review of systematic reviews and updated meta-analyses of observational studies. Systematic Reviews. 2017;6(1):69. DOI: 10.1186/s13643-017-0466-y
2. Organization WH. Neurological Disorders Affect Millions Globally: WHO report. World Health Organization; Switzerland. 2007. Available from: http://www.who.int/mental_health/neurology/neurological_disorders_report_web.pdf
3. Agrawal M, Ajazuddin TDK, Saraf S, Saraf S, Antimisiaris SG, Mourtas S, et al. Recent advancements in liposomes targeting strategies to cross blood-brain barrier (BBB) for the treatment of Alzheimer's disease. Journal of Controlled Release. 2017;260:61-77. DOI: 10.1016/j.jconrel.2017.05.019
4. Bourganis V, Kammona O, Alexopoulos A, Kiparissides C. Recent advances in carrier mediated nose-to-brain delivery of pharmaceutics. European Journal of Pharmaceutics and Biopharmaceutics. 2018;128:337-362. DOI: 10.1016/j.ejpb.2018.05.009
5. Montesinos R. Liposomal drug delivery to the central nervous system. In: Catala A, editor. Liposomes. London: IntechOpen; 2017. DOI: 10.5772/intechopen.70055